Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer.
about
Pancreatic cancer: New hopes after first line treatmentOral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer.Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting.Salvage therapy with mitomycin and ifosfamide in patients with gemcitabine-resistant metastatic pancreatic cancer: a phase II trial.Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma.Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinomaHigh expression of erythropoietin-producing hepatoma cell line-B2 (EphB2) predicts the efficiency of the Qingyihuaji formula treatment in pancreatic cancer CFPAC-1 cells through the EphrinB1-EphB2 pathway.FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM studyCombination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301).Overcoming drug resistance in pancreatic cancer.Systemic therapy for metastatic pancreatic adenocarcinoma.A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancerSecond-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials.The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer.Gemcitabine in the treatment of metastatic pancreatic cancer.Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options?Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure.Lentivirus-mediated overexpression of TGF-β inducible early gene 1 inhibits SW1990 pancreatic cancer cell growth.Role of taxanes in pancreatic cancer.Weekly Paclitaxel after failure of gemcitabine in pancreatic cancer patients with malignant ascites: a retrospective study.S-1 monotherapy as second-line treatment for advanced pancreatic cancer after gemcitabine failure.Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study.Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial.Sustained Disease Control with TOMOXIRI Regimen in a Patient with Metastatic Pancreatic Adenocarcinoma.Second-line therapy in advanced upper gastrointestinal cancers: current status and new prospects.Current status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining?
P2860
Q28067055-9621B422-044D-475D-8848-9F6DC1B6C854Q33382236-781498DB-CE61-4512-89B6-35D09F7226CAQ33394190-B1ECB8C4-3C2F-4DF9-A559-20FAC2F9B31FQ33394729-0F22D7E6-DE2D-4592-8A73-9BC3BCF077A3Q33428382-23A3E703-7CFF-4268-AAA3-4FA7E7C04D4EQ33751227-276B2F85-C766-43F7-91C1-D18AEA8E6C90Q33778296-B60BD8D8-10A0-4700-8073-39138B60F184Q33823212-6D0EAF40-F9BF-4487-BD0D-EA86C2F3E077Q34308370-0A0C7EC0-D2EB-4AB1-A6F4-5CCF7FA640FAQ35036615-A7BAF418-E396-4ACB-86DD-1E4B6F5ED966Q35076238-6132FB2F-F380-40C5-BA48-EE6F286C1A70Q36610441-9BB9C437-DD87-41BB-A7C1-038AA72879DAQ37032865-52A2E0CA-F728-4ACA-8B42-14389F3D75E8Q37074126-52F5B8B1-238F-4CFF-B3A7-95570C3781C1Q37134412-21138A11-0237-48D7-B25E-8CC159163CBEQ37617955-07D0EAB8-A912-4D57-9095-84356E997D60Q38577917-4F0F6115-C97A-4F86-9E47-F8BACC0E210BQ39552151-5FCA9D7B-D7C8-481C-B9A7-4767232671CDQ42323567-DB441767-4CD2-4565-B3C7-1CBDD627F6FBQ42959222-BF7EAC99-1BB3-4B0D-948B-16A02AD1A350Q43147217-B213FFBF-1361-490D-8876-82BDDFC84409Q44916594-F0FB0E3B-1EFA-4A3D-98B5-8E0AC48EB5D5Q48825323-2D692D73-66C6-4CA8-914A-DCCDCE463D2FQ53561339-F2BBD2C0-295A-4824-B900-D3C721538190Q55223567-A757B1EA-1AD6-4559-A277-C92D26798A7FQ58799265-462C0602-9E24-4383-B064-15E1C773678E
P2860
Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մարտին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Raltitrexed-eloxatin salvage c ...... metastatic pancreatic cancer.
@ast
Raltitrexed-eloxatin salvage c ...... metastatic pancreatic cancer.
@en
type
label
Raltitrexed-eloxatin salvage c ...... metastatic pancreatic cancer.
@ast
Raltitrexed-eloxatin salvage c ...... metastatic pancreatic cancer.
@en
prefLabel
Raltitrexed-eloxatin salvage c ...... metastatic pancreatic cancer.
@ast
Raltitrexed-eloxatin salvage c ...... metastatic pancreatic cancer.
@en
P2093
P2860
P356
P1476
Raltitrexed-eloxatin salvage c ...... t metastatic pancreatic cancer
@en
P2093
C Milandri
P2860
P2888
P304
P356
10.1038/SJ.BJC.6603026
P407
P577
2006-03-01T00:00:00Z
P5875
P6179
1028056239